Speakers

Expand/Collapse

Jessica Morris
Diagnosed with GBM January 2016, Founder & Chair
OurBrainBank

Jessica founded OurBrainBank following her diagnosis of GBM in 2016. The organization’s mission and approach reflect her 35 years of strategic communications and campaigning.   OurBrainBank enables people with GBM to track their symptoms via a certifed, free app, and donate their data to research. It launched in 2018, and has since exhibited and had abstracts published by SNO and ASCO. Jessica was honored as a Hero of Hope by the Academy of Oncology Patient & Nurse Navigators.   Jessica was SVP and Partner of FleishmanHillard when she was diagnosed. Previously, she co-created a global exhibition on the future of cities for the Institute of Transportation & Environment Policy, and has created campaigns for clients ranging from Mastercard and Barclays to the UK’s National Health Service, and the UN.  
Jessica founded The Sheila McKechnie Foundation, and served on the boards of ITDP, Committee on Sustainability Assessment, and the Communications Advisory Board of Human Rights Watch.

Day One

Tuesday, December 10, 2019

8:30 am | Living With Glioblastoma: A Licence to Be Ambitious

Moshe Giladi
Director of Preclinical Research
Novocure

Dr. Giladi leads Novocure preclinical development overseeing all preclinical activities and external research collaborations.  Dr. Giladi was previously the head of NovoBiotic, Novocure spinoff company, focusing on treatment against infectious diseases. He received his BS in Biology, MS in Microbiology and Entomology, Ph.D. in Molecular Microbiology and Biotechnology and MBA, all from Tel Aviv University.

Day One

Tuesday, December 10, 2019

11:50 am | TTFields – a Perfect Match with Other Modalities in GBM

Fahar Merchant
President & CEO
Medicenna Therapeutics

  Dr. Merchant is a 25-year biotech veteran, a serial entrepreneur and co-founder of Medicenna. Previously he was President and CEO of Protox Therapeutics (TSX; now Sophiris Bio, Nasdaq) where he established a late clinical stage uro-oncology company. In 1992 he co-founded IntelliGene Expressions, Inc., a biologics CDMO, and built it into one of the fastest growing companies in Canada. In 2000, by strategic in-licensing, he co-founded Avicenna Medica, Inc., a clinical stage oncology company that was sold a year later to KS Biomedix (LSE). Fahar was CTO and Director of KS Biomedix until its acquisition by Xenova (Nasdaq and LSE). He has a PhD in Biochemical Engineering from Western University.

Day Two

Wednesday, December 11, 2019

10:10 am | Clinical Case Study: Using a Multi-pronged Approach to Treating Recurrent GBM: Overcoming the Tumor and its Microenvironment

Laurence Cooper
Chief Executive Officer
Ziopharm Oncology

Laurence joined Ziopharm Oncology as chief executive officer in 2015 from MD Anderson Cancer where he was a tenured professor in the Division of Pediatrics and Department of Immunology. There, he served as Section Chief of Cell Therapy at the Children’s Cancer Hospital and helped lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. Laurence has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing genetically modified T cells and virus. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and he completed his training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.

Day Two

Wednesday, December 11, 2019

2:40 pm | IL-12 as a Drug for Recurrent Glioblastoma: Genetic Engineering to Control this Master Regulator of the Immune System

Adilia Hormigo
Director Neuro-Oncology Division, Icahn School of Medicine
Mount Sinai & The Tisch Cancer Institute

Adilia earned her MD at Faculdade de Medicina da Universidade de Lisboa, and her PhD at New York University. She completed postgraduate clinical training in Neurology at Cornell University and clinical and research neuro-oncology fellowships at Memorial Sloan-Kettering Cancer Center where she served as faculty. Adilia’s research focuses on developing personalized medicine to treat patients with brain tumors. She uses a multidisciplinary approach that includes neuropathology, bioinformatics, biochemistry and the Cancer Vaccine and Cell Therapy laboratory at the Tisch Cancer Institute to develop a new immunotherapy-based treatment. Mutations in glioblastoma lead to the formation of neoantigens. These neoantigens are not present in normal cells. Her treatment targets those neoantigens to activate the immune system and eliminate the cancer cells. Adilia’s team is also developing new methods to increase drug penetration to the brain and to determine other approaches that will enhance the effect of immunotherapy.

Day Two

Wednesday, December 11, 2019

12:10 pm | Active Clinical Trial: Developing Personalized Cancer Vaccines for Newly Diagnosed Glioblastoma

Antonio Chiocca
Neurosurgeon-in-chief & Chairman
Brigham & Women’s

Dr. Chiocca is the Harvey Cushing Professor of Neurosurgery at Harvard Medical School and is the Chairman Neurosurgery at the Brigham and Women’s Hospital.  He was previously Chairman of the Department of Neurosurgery at the Ohio State University Medical Center.  He has been continuously funded by the NIH since 1996. He has more than 300 peer-reviewed publications, some in journals such as Nature Medicine, Nature Biotechnology, Molecular Cell, and PNAS.  He has elucidated how viruses with specific gene mutations will replicate selectively in tumors with a specific defect in a tumor suppressor pathway. He has also shown how modulation of innate immunity will improve replication of these tumor-selective viruses. More recently, he has elucidated how specific microRNAs (mir128 and mir451) regulate cellular target transcripts to permit tumor cell self-renewal and invasion into brain. He has been PI of three multi-institutional clinical trials of gene-, viral-therapies for malignant gliomas, has been permanent member of NIH study sections (NCI DT and NCI P01-D clinical studies), has been a member of the federal recombinant DNA Advisory Committee (RAC/OBA) and of the NINDS Scientific Advisory Council. In 2013, he was elected Vice-President of the Society for Neuro-Oncology (SNO).  He was President of SNO from 2015-2017.. He is currently President of the American Academy of Neurological Surgery and Member at large of the Society of Neurological Surgery and American Association of Neurological Surgery. He also serves on the scientific advisory board of several foundations (Sontag, American Brain Tumor Association).  He received The Grass Award in 2007, the Farber Award in 2008 and the Bittner Award in 2013.  He was elected to the American Society for Clinical Investigation (2005), is an AAAS fellow (2005) and was also elected to the National Academy of Medicine (formerly Institute of Medicine) in 2014.  He received the Charles B. Wilson Career Achievement Award from the CNS/AANS Section on Tumors in 2018 and the Victor Levin Award for Achievement in neuro-ocnology from SNO in 2018.  He also has served on multiple editorial boards and is the current Tumor Section Editor for Neurosurgery and Associate Editor for Neuro-oncology. He was on the editorial board of Journal of Neurosurgery from 2005 until 2012.

Day Two

Wednesday, December 11, 2019

9:40 am | Clinical Case Study: Exploring Gene & Viral based Immunotherapies for Glioblastoma

Christophe Quéva
Chief Scientific Officer
Oncorus

Christophe Quéva, Ph.D., is Chief Scientific Officer and Senior Vice President, Research. Christophe is responsible for directing and advancing the company’s development program based on its next-generation immunotherapy platform of oncolytic viruses. An industry veteran, Christophe has nearly two decades’ immuno-oncology experience and successful portfolio-building track record from target identification and development through regulatory approval. Prior to joining Oncorus, Christophe was Chief Scientific Officer at iTeos Therapeutics where his responsibilities included leading the generation of an innovative immuno-oncology portfolio of small molecule and antibody programs. Before iTeos, he held successive senior positions at AstraZeneca, Amgen and Gilead Sciences where he led or supported drug discovery programs for oncology and inflammatory diseases, from target selection to commercial approval for small molecules and biologics.
A holder of five patents and widely published, Christophe trained as a post-doctoral fellow at the Fred Hutchinson Cancer Research Center in Seattle after receiving his Ph.D. in Life and Health Sciences from the University of Lille, France.

Day One

Tuesday, December 10, 2019

9:50 am | Developing Next-Generation Oncolytic Viruses for the Immunotherapy of GBM

David Nathanson
Assistant Professor
UCLA

David Nathanson is an Assistant Professor in the Ahmanson Translational Imaging Division (ATID) in the Department of Molecular and Medical Pharmacology at UCLA. Dr. Nathanson received his B.S. from Willamette University and his Ph.D in Molecular and Medical Pharmacology under Dr. Paul Mischel at UCLA. He was then a post-doctoral fellow in the lab of Dr. Caius Radu at UCLA. Dr. Nathanson’s lab focuses on the interplay between aberrant signal transduction and metabolism in glioblastoma (GBM), the most lethal brain tumor in adults, and developing new therapeutic strategies to treat this deadly disease.

Day One

Tuesday, December 10, 2019

9:20 am | An Interdisciplinary Approach to Deciphering the Biology of GBM to Develop Innovative Therapies

Douglas Jolly
Executive VP
Tocagen

Douglas Jolly is a founder of Tocagen in 2007 and is currently Executive Vice President, Research and Pharmaceutical Development. Dr. Jolly is an internationally recognized expert in the field of gene therapy and its pharmaceutical application. Over the last 30 years he has been a senior biotechnology executive involved in translating gene-based products from research through clinical development at the following companies: Viagene, Inc., where he was also a co-founder, Chiron Corporation, Oxford BioMedica plc,, and Advantagene, Inc. Before entering the biopharmaceutical industry, Dr. Jolly pursued his academic career in biophysics and molecular biology at the Weizmann Institute, Harvard Medical School, the University of California, San Diego and INSERM, in Paris, France. Dr. Jolly holds a Ph.D. in Biochemistry from the University of Glasgow and has served as a board member of the American Society of Gene & Cell Therapy and also chairman of the Industrial Liaison Committee.

Day Two

Wednesday, December 11, 2019

11:10 am | Clinical Case Study: Immmuno-Gene Therapy - Selectively Infecting Cancer Cells to Stimulate Robust & Durable Anti-Cancer Immune Responses

Ed Reilly
Distinguished Research Fellow
AbbVie

Ed is a cancer biologist who originally trained as a Postdoctoral Fellow and Visiting Scientist at the MIT Center for Cancer Research. He has extensive experience in oncology and immunology in the biotech and pharma research arenas.  At AbbVie, he initiated the antibody drug conjugate (ADC) platform and was responsible for advancing multiple ADCs to the clinic including several EGFR-targeted ADCs in glioblastoma patients.  More recently he instituted AbbVie’s soluble T cell receptor program for the identification of novel cancer therapeutics.  Presently Ed serves as a Distinguished Research Fellow and Project Director in Oncology Discovery where he leads several late stage Discovery programs.

Day One

Tuesday, December 10, 2019

2:20 pm | Pre-clinical Justification & Validation for Targeting EGFR Expressing Glioblastoma with Potent Tumor-Selective Antibody Drug Conjugates

James Garner
Chief Executive Officer & Managing Director
Kazia Therapeutics Limited

Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation. He has been responsible for several large-scale international clinical programs, and for numerous product approvals in multiple countries. Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia Therapeutics in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.  Dr Garner is a member of the Australian Institute of Company Directors.

Day Two

Wednesday, December 11, 2019

3:40 pm | Realizing Potential: Taking GDC-0084 Forward in Glioblastoma

James Stuart
Medical Director
Innovate Pharmaceuticals

James is a board-certified Emergency Physician working in Manchester England. He trained as a physician in London, Belfast, Brisbane and Manchester. He won the John Simon prize (University of London) in 1985 and the Seton Scholarship in 1994 and 2000.  His team founded Innovate Pharmaceuticals Ltd in 2015 and have developed IP1867B which has shown efficacy against GBM in our preclinical work. James has been the medical director of Innovate Pharmaceuticals Ltd since its creation.  

Day One

Tuesday, December 10, 2019

5:30 pm | A Multi-Mechanistic Approach in Overcoming Tumor Resistance; Combining Existing Approved Drugs for Novel Formulation Techniques

Jann Sarkaria
Professor of Radiation Oncology
Mayo Clinic

Jann N. Sarkaria, M.D., is a consultant in the Department of Radiation Oncology at Mayo Clinic in Rochester, Minnesota and holds the academic rank of professor of radiation oncology, Mayo Clinic College of Medicine and Science. Dr. Sarkaria earned his B.S. in biology and chemistry from the University of California at Irvine and his M.D. at the University of California Los Angeles. He completed an internship at the University of Hawaii, followed by a radiation oncology residency at the University of Wisconsin. During residency, he was awarded fellowships from the American Society of Therapeutic Radiology and Oncology and from the National Institutes of Health to support a research fellowship in radiobiology at the Institute for Cancer Research in Sutton, England. He continued his training through a postdoctoral research fellowship in the Department of Oncology at Mayo Clinic. Dr. Sarkaria’s translational neuro-oncology laboratory is focused on developing novel therapeutic strategies for people with glioblastoma (GBM) and brain metastases. Global interests in the lab include understanding the basis of resistance to chemotherapy and radiation, identifying methods to overcome therapy resistance, integration of novel signal transduction inhibitors into conventional therapies for newly diagnosed or recurrent GBM, and use of next-generation sequencing and proteomics to guide individualized therapy for patients with GBM. His research is funded by the National Institute of Neurological Disorders and Stroke and the National Cancer Institute.

Day One

Tuesday, December 10, 2019

5:00 pm | Pre-Clinical Evaluation of Novel Therapeutics

Jeffrey Skolnik
Vice President
Inovio Pharmaceuticals

Dr. Skolnik oversees all of Inovio’s cancer immunotherapy programs, as well as those for several infectious diseases. Dr. Skolnik was previously at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, and oversaw all clinical programs in oncology, infectious diseases and dermatology. He was also a Medical Affairs lead in oncology at GSK and held several positions at AstraZeneca including Senior Director for both early and late stage compounds. Dr. Skolnik is also a practicing pediatric Hematologist-Oncologist, and has published several papers regarding pediatric oncology trial design.

Day Two

Wednesday, December 11, 2019

4:40 pm | Clinical Case Study: Inovio’s Innovative Combination Trial

Kirk Tanner
Chief Scientific Officer
National Brain Tumor Society (NBTS)

Kirk Tanner is the Chief Scientific Officer at the National Brain Tumor Society. Kirk is an oncology research leader with two decades experience in discovery and development projects and programs resulting in multiple clinical candidate therapies and investigational new drugs. Formerly, he was the Research Oncology Disease Area Expert and Senior Director at Vertex Pharmaceuticals. As CSO, Kirk leads National Brain Tumor Society’s research program that aims to catalyze treatment development through philanthropic investment in medical research, engaging scientists, clinicians, patients and care partners in research programs. Kirk received his Ph.D. in chemistry from the University of California, San Diego and did post-doctoral training at Oregon Health Sciences University  

Day One

Tuesday, December 10, 2019

6:30 pm | Panel Discussion

3:50 pm | Panel Discussion: Realizing the Economic Reality of Working on GBM

Day Two

Wednesday, December 11, 2019

8:30 am | Chair’s Opening Remarks

Laurent Salphati
Principal Scientist
Genentech

Dr. Laurent Salphati is currently a Principal Scientist in the Drug Metabolism and Pharmacokinetics department at Genentech, Inc. He heads the Permeability/Drug Transporters group and has been supporting and leading immunology neuro-oncology and oncology projects from preclinical discovery to late stage clinical development. He received his Pharm.D. from the University of Paris XI, France, and conducted his Ph.D. research, investigating the complementary roles of P-glycoprotein and CYP3A in drug absorption and disposition, at the University of California, San Francisco under the guidance of Dr. Leslie Z. Benet. His research interests include the pharmacokinetics and pharmacodynamics of drugs - PKPD and PBPK modeling - and the role of drug transporters in drug absorption and disposition.

Day Two

Wednesday, December 11, 2019

2:10 pm | Discovery & Preclinical Development of a PI3K Inhibitor for the Treatment of Glioblastoma

Marnix Bosch
CTO
Northwest Biotherapeutics

Dr. Bosch joined Northwest Biotherapeutics in 2000, and has been serving as Chief Technical Officer for a number of years. In this capacity, he plays a key role in the preparation and submission of regulatory applications, and ongoing development of existing processes and/or acquisition of new technologies. Dr. Bosch led the process of designing the protocols, and managed the successful preparation and submission of Investigational New Drug (IND) applications for FDA approval to conduct clinical trials for prostate cancer, brain cancer, ovarian cancer and multiple other cancers. He also led the processes for other regulatory submissions in both the U.S. and abroad (including the successful applications for orphan drug status in both the U.S. and Europe for DCVax-L for brain cancer). He spearheaded the development of manufacturing and quality control processes, and is working with Cognate BioServices, Inc. on next-generation further development of these processes. Prior to joining NWBio in 2000, Dr. Bosch worked at the Dutch National Institutes of Health (RIVM) as head of the Department of Molecular Biology, as well as in academia as an associate professor of Pathobiology at the University of Washington. He has authored more than 40 peer-reviewed research publications in immunology and virology, and is an inventor on several patent applications on dendritic cell product development.

Day Two

Wednesday, December 11, 2019

11:40 am | DCVax Technology: Leveraging Activated Dendritic Cells in Clinical Development for GBM

Patrick Wen
Director, Center For Neuro-Oncology
Dana-Farber/Brigham & Women’s Cancer Center

Dr. Patrick Wen is a Professor of Neurology at Harvard Medical School, President of the Society For Neuro-Oncology, Co-PI of thr Adult Brain Tumor Consortium and former Editor-In-Chief of Neuro-Oncology. He received his medical degree from Barts and The London School of Medicine and Dentistry and completed his neurology residency in the Harvard-Longwood Neurology Training Program.

Day One

Tuesday, December 10, 2019

8:50 am | High Level Global Overview of Research & Clinical Development to Date for GBM

Ranjit S. Bindra
Associate Professor of Therapeutic Radiology
Yale School of Medicine

Dr. Ranjit Bindra is a physician-scientist at the Yale School of Medicine and Co-Director of the Yale Brain Tumor Center. In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and it has received international attention with major clinical implications. Follow-up studies from his group subsequently were published in Nature Genetics, and Nature Communications. Dr. Bindra is now translating this work directly into patients in four phase I/II clinical trials. As a biotech entrepreneur he recently co-founded Cybrexa Therapeutics, a Series B round-funded company focused on developing an entirely new class of small molecule DNA repair inhibitors, which directly target the tumor microenvironment.

Day One

Tuesday, December 10, 2019

2:50 pm | Targeting DNA Damage Response Pathways for GBM

Sharon Shacham
President & Chief Scientific Officer, Co-founder
Karyopharm

Dr. Shacham founded Karyopharm in 2008 and has served as our Chief Scientific Officer and President of Research and Development since December 2012. From 2010 to 2012, Dr. Shacham served as our Chief Scientific Officer and Head of Research and Development, and prior to that, as our President and Chief Executive Officer. Dr. Shacham has led our scientific progress since inception.

Prior to joining Karyopharm, Dr. Shacham served as Senior Vice President of Drug Development at Epix Pharmaceuticals, Inc., and Director, Algorithm and Software Development at Predix Pharmaceuticals Inc., which merged into Epix Pharmaceuticals in 2006, and where she led the company’s efforts in GPCR modeling, computational chemistry, lead optimization and development of clinical trials.

Dr. Shacham holds a Bachelor of Science in Chemistry, along with a Doctor of Philosophy and a Master of Business of Administration from Tel Aviv University.

Day Two

Wednesday, December 11, 2019

4:10 pm | Clinical Case Study: Driving a New Therapeutic Strategy to Accelerate to the Clinic

Stephen Durant
Associate Principal Scientist
AstraZeneca

Steve has studied the DNA Damage Response (DDR) in cancer for over 20 years starting with a PhD on DNA double strand break (DSB) and mismatch repair in chemo-resistance at the Beatson Institute, UK. After three postdoctoral fellowships (CRUK Clare Hall UK, the University of New Mexico, USA and University of Oxford, UK) studying mechanisms of DSB repair, Steve joined KuDOS Pharmaceuticals in Cambridge as New Targets Team Leader. He then joined AstraZeneca building the DDR New Targets area and leading the pre-clinical work supporting the development of brain-penetrant ATM inhibitors to radiosensitise brain tumour models. This work led to AstraZeneca taking AZD1390 into clinical development. Steve now works at AstraZeneca’s Cambridge UK sites continuing to lead research and academic collaborations on ATM inhibition, new targets, synthetic lethal exploitation and helps to triage in-licensing proposals. Steve has supervised industrial undergraduates, PhD students and AZ-funded postdocs publishing in high impact journals and won AZ publication awards along the way.

Day One

Tuesday, December 10, 2019

3:20 pm | Pre-clinical, Translational & Clinical Development of AZD1390 - the Brain-Penetrant ATM inhibitor in a Phase 1 GBM Clinical Trial

Thomas N. Seyfried
Professor
Boston College

Thomas N. Seyfried is Professor of Biology at Boston College, and received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He also holds a Master's degree in Genetics from Illinois State University, Normal, IL. Thomas Seyfried served with distinction in the United States Army’s First Cavalry Division during the Vietnam War, and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine, and then served on the faculty. He serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, Frontiers in Nutrition, Frontiers in Oncology, and ASN Neuro, where his is a Senior Editor. Dr. Seyfried has over 185 peer-reviewed publications and is author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press). His book was recently translated into Chinese, and his full list of peer-reviewed publications can be found on PubMed (www.ncbi.nlm.nih.gov/pubmed/?term=Seyfried+TN)

Day One

Tuesday, December 10, 2019

11:20 am | Trailblazing a Paradigm Change - Developing a General Protocol of Treatment for GBM Patients: Metabolic Therapy

Timothy Cloughesy
Director, Neuro-Oncology Program, Professor
UCLA

Dr. Cloughesy is a Professor of Neurology at the David Geffen School of Medicine at UCLA. His research has focused on clinical trials in brain cancer using targeted molecular/immune therapies with novel clinical trial design and biomarkers in brain cancer. He is the global PI for the master protocol GBM Agile.

Day Two

Wednesday, December 11, 2019

9:10 am | Coaxing T-cells into Action: Leveraging a Rational & Logical Way to Develop Immunotherapies

William F. Elmquist
Professor and Director of the Brain Barriers Research Center
University of Minnesota

William F. Elmquist is currently Professor and Director of the Brain Barriers Research Center, at the University of Minnesota, Department of Pharmaceutics.  He received his pharmacy degree at the University of Florida, and Pharm.D. and Ph.D. (pharmacokinetics) from the University of Minnesota.  His research has studied the influence of active efflux transporters in the blood-brain barrier (BBB) on CNS drug distribution.  An important project currently underway is examining the determinants of anticancer drug permeability in the blood-brain barrier to improve the treatment of brain tumors.  Long-term objectives of Dr. Elmquist's research include examining expression and regulation of transport systems in key tissues that influence drug disposition, and how variability in expression, either genetically or environmentally controlled, may contribute to variability in drug response in the patient.  Dr. Elmquist has long been a consultant to the pharmaceutical industry and the NIH, served on many journal editorial boards, and is a Fellow of the American Association of Pharmaceutical Scientists (AAPS).

Day One

Tuesday, December 10, 2019

12:20 pm | Examining the Determinants of Anticancer Drug Permeability in the Blood-Brain Barrier

Michael Lim
Director of the Brain Tumor Immunotherapy Program
Johns Hopkins University School of Medicine

Day Two

Wednesday, December 11, 2019

8:40 am | Assessing the Current State of Immunotherapy for GBM

Josep Garcia
Global Development Lead for Avastin
Roche-Genentech

Day One

Tuesday, December 10, 2019

6:00 pm | A Retrospective Look at the Journey of Avastin in GBM: “Back to the Future”

Brian Alexander
Associate Professor of Radiation Oncology, Harvard Medical School & Dana-Farber/ Brigham and Women’s Cancer Center
GBM Agile Global Coalition for Adaptive Research

Dr. Alexander is Chief Medical Officer of Foundation Medicine, Inc. and an Associate Professor of Radiation Oncology at Harvard Medical School and Dana-Farber/Brigham and Women’s Cancer Center. He also founded the Program in Regulatory Science at the Dana-Farber Cancer Institute and is a Member of the Scientific Council of the Harvard/MIT Center for Regulatory Science. Dr. Alexander received his B.A. from Kalamazoo College, M.D. from the University of Michigan Medical School, and M.P.H. from the Harvard School of Public Health. He completed his training in radiation oncology at the Harvard Radiation Oncology Program. Dr. Alexander’s research interests focus on innovations in clinical evidence generation to support the development of therapeutics, biomarkers, and novel endpoints. Dr. Alexander co-authored a book entitled “Diagnostic Test Interpretation and Reasoning Under Uncertainty,” detailing the use of Bayesian approaches to clinical decision-making and is the recipient of the Burroughs-Wellcome Innovations in Regulatory Science Award for his work applying such approaches to clinical trial design. Dr. Alexander was the founding principal investigator of INSIGhT, a multi-institutional genomic biomarker-based Bayesian adaptively randomized trial for patients with glioblastoma. Prior to his faculty appointment at Harvard Medical School, Dr. Alexander served as a White House fellow and Special Assistant to the Secretary of Veterans Affairs. In that role, he helped prepare the VA for the transition of administrations, worked to develop a public reporting system for quality, and served as a health policy advisor to the Secretary. Dr. Alexander organized the standup of the VA’s Coordinating Council on National Health Reform and directed the activities of its multi-team Health Reform Working Group. He was also a member of the Institute of Medicine’s Committee on the Governance and Financing of Graduate Medical Education.

Day Two

Wednesday, December 11, 2019

1:40 pm | GBM Agile: Identifying More Effective Therapies for the Right Patients Faster

John Gainer
Chief Scientific Officer, Co-founder
Diffusion Pharmaceuticals

BS, MS, PhD;  Chief Science Officer of Diffusion Pharmaceuticals Inc., Charlottesville, Virginia, USA;  Professor for 40 years at University of Virginia with sabbaticals at Pharmacology Department, Karolinska Institute, Stockholm, Sweden and ICI Pharmaceuticals, Alderley Edge, England;  invented TSC for treating battlefield casualties under grant from  US Office of Naval Research.

Day One

Tuesday, December 10, 2019

1:50 pm | TSC Treats GBM by Reducing Hypoxia: A Novel Approach